Work with LifeSpan to design a custom immunohistochemistry to address your specific biological question. Outsource the entire localization process without having to
worry about finding and characterizing target specific antibodies, sourcing and validating difficult-to-find tissues, and having the ability to interpret the resulting
immunostaining in relation to complex human pathologies.
TCR Screening Services
Test your therapeutic antibodies in immunohistochemistry against a broad panel of normal frozen human tissue types in order to determine potential unintended binding.
Our non-GLP TCR services are designed on the FDA recommendation outlined in their "Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use".
LS-F39692 is a 96-well enzyme-linked immunosorbent assay (ELISA) for the Quantitative detection of Mouse CTF1 / Cardiotrophin-1 in samples of Cell Culture Supernatants, Plasma and Serum. It is based upon a Sandwich assay principle and can be used to detect levels of CTF1 / Cardiotrophin-1 as low as 10 picograms per milliliter.
Cell Culture Supernatants, Plasma, Serum
96-Well Strip Plate
Colorimetric - 450nm (TMB)
156 - 10000 pg/ml
Intra-Assay: CV%<6.2% Inter-Assay: CV%<7.4%
Due to their limited shelf life, LSBio ELISA kits are not typically stocked as finished goods. Upon receipt of an order each kit is assembled and tested to ensure that it meets specifications before shipping. Minor changes may occur to the Range, Sensitivity, and Precision. In the event of a significant change the order would be confirmed with the customer before shipping ELISA kit lot numbers reflect the date of final assembly and testing for each specific kit rather than a bulk manufactured lot. All kits are tested to confirm that they fall within their defined Inter- and Intra- assay coefficient of variation.
CTF1 / Cardiotrophin-1 is a cytokine. It is a cardiac hypertrophic factor of 21.5 kDa and a protein member of the IL-6 cytokine family. CT-1 is associated with the pathophysiology of heart diseases, including hypertension, myocardial infarction, valvular heart disease, and congestive heart failure. The protein exerts its cellular effects by interacting with the glycoprotein 130 (gp130)/leukemia inhibitory factor receptor beta (LIFR) heterodimer.